Table 1.
SULT1A1 genetic variation in vivo and therapeutic agents.
| Study (year) | Cancer site | Population | Cases/controls (n) | Main findings | Ref. |
|---|---|---|---|---|---|
| Nowell et al. (2002) | Breast | African–American and Caucasian American | 337 cases (160 with TAM, 177 without TAM) | Increased risk of death with SULT1A1*2/*2 | [13] |
| Nowell et al. (2005) | Breast | African–American and Caucasian American | 162/175 | Significantly increased risk of recurrence and 5-year survival with UGT2B15*2 and SULT1A1*2/*2 | [14] |
| Wegman et al. (2005) | Breast | Swedish | 226 TAM treated cases | Significantly decreased risk of recurrence with CYP2D6*4 and SULT1A1*1/*1 | [15] |
| Wegman et al. (2007) | Breast | Swedish (Stockholm Breast Cancer Group) | 677 TAM treated cases | Significantly improved recurrence-free survival with treatment for 2 years and SULT1A1*1 | [16] |
| Tengström et al. (2012) | Breast | Finnish | 412 (76 treated with cyclophosphamide, 65 with TAM, four with both) | Significantly improved overall survival and moderately improved breast cancer specific survival associated with TAM or chemotherapy and SULT1A1*2/*2 NA with relapse-free survival | [19] |
| Grabinski et al. (2006) | Breast | Caucasian and Hispanic | 296 TAM treated cases | NA with age, tumor size, histological grade, stage of disease, menopausal status, HER2 overexpression, and ER or PR status | [20] |
| Serrano et al. (2011) | Breast | Caucasian (Italian Tamoxifen Prevention Trial) | 46 (20 cases treated with TAM, 26 cases received placebo)/135 (65 controls treated with TAM, 71 controls received placebo) | NA with breast cancer risk | [21] |
| Knechtel et al. (2010) | Breast | Austrian | 216 LN+ cases treated with TAM, hormone, anthracycline or nonanthracycline therapy | NA with either disease-free or overall survival | [17] |
| Moyer et al. (2011) | Breast | Mixed, but 95% Caucasian | 190 on TAM monotherapy | NA between either disease-free survival or recurrence and SULT1A1 copy number | [18] |
| Jin et al. (2005) | Breast | Mixed, but 91% Caucasian | 80 TAM treated cases | NA with TAM and metabolite serum concentrations Trend toward increase in 4-OHT and endoxifen with SULT1A1*2/*2 | [22] |
| Gjerde et al. (2008) | Breast | Caucasians in Norway | 151 TAM treated cases | NA with TAM and metabolite serum concentrations for either genotype or copy number Significant trend between increasing SULT1A1*1 alleles and serum metabolite ratios (+NDtam/TAM and -NDDtam/NDtam) |
[23] |
| Fernandez-Santander et al. (2013) | Breast | Spanish Caucasians | 135 TAM treated cases | NA with TAM and metabolite serum concentrations | [24] |
| Innocenti et al. (2013) | Multiple | Mixed | 47 ABT-751 treated cases | Increased clearance and metabolic ratios and decreased AUC with >2 copies | [25] |
AUC: Area under the curve; LN+: Lymph node positive; NA: No association; NDtam: N-demethyltamoxifen; TAM: Tamoxifen.